PROVIDING ADVANCED MEDICAL TECHNOLOGY FOR ALL.
Today’s doctors, face the delicate challenge of diagnosis everyday but the tools available to them are far from perfect. Medical practitioners often have to trade off performance with convenience.
Focusing on research and development of revolutionary diagnostic technologies since 2011, Credo Diagnostics develops, manufactures, and commercializes an accurate, rapid and affordable molecular diagnostic platform at the Point-Of-Care: the VitaPCR.
Conscious of the necessity to simplify processes and accelerate diagnostics turnaround times at lower costs while ensuring the best accuracy, we provide solutions for diagnosis in the areas of Human Health.
The diagnostic companies have a moral responsibility and duty to the doctors and patients to provide better tools, and we envision that effective rapid POC Molecular Diagnostics will redefine healthcare for human clinical management.
SEE WHO IS TALKING ABOUT US
HISTORY
2011
Credo Diagnostics
Was founded in Singapore.
2014
Trentron Biomedical
A wholly owned subsidiary was set up in Taiwan.
2019
Breakthrough INNOVATION for POCT
- Launched VitaPCR™ Instrument and Influenza A&B assay at AACC.
- Obtained CE certificate for Influenza A&B assay.
2020
Detect COVID-19 in 20 mins
- Obtained CE certificate for SARS-CoV-2 assay and combo assays for Flu/SARS-CoV-2, Flu/RSV.
- Obtained HSA provisional authorization for SARS-CoV-2 assay in Singapore.
2021
Launch Connectivity Solution
- Launched VitaDataLink connectivity software for data management.
- Ability to export data in HL7 format for patient database management (LIS).
2021
2021 The establishment of Credo Diagnostics Biomedical Pte. Ltd. Taiwan Branch
More than 8,000 VitaPCR™ instruments have been installed all over the world.